
Claims

1. A pharmaceutical composition, comprising:

a) a compound shown in formula (I);



(I)

b) a solubilizing agent;

c) other pharmaceutically acceptable excipients.

2. The pharmaceutical composition of claim 1, comprising, in weight parts:

a) 1 part compound shown in formula (I);

b) 0.2 to 15 parts of a solubilizing agent;

c) 1 to 25 parts of other pharmaceutically acceptable excipients.

3. The pharmaceutical composition of claim 1 or 2, comprising, in weight parts:

a) 1 part compound shown in formula (I);

b) 0.2 to 15 parts of polyvinylpyrrolidone as solubilizing agent;

c) 1 to 25 parts of other pharmaceutically acceptable excipients.

4. The pharmaceutical composition of any one of claims 1 to 3, comprising, on a weight-portion basis,

1 part of the compounds shown in formula (I);

1 to 10 parts of polyvinylpyrrolidone; and

1.7 to 20 parts of other pharmaceutically acceptable excipients.

5. The pharmaceutical composition of any one of claims 1 to 4, wherein the other pharmaceutically acceptable excipients are selected from the group consisting of fillers, disintegrants, lubricants and glidants.

6. The pharmaceutical composition of any one of claims 1 to 5, wherein the other pharmaceutically acceptable excipients comprise a filler selected from the group consisting of lactose, mannitol, silicified microcrystalline cellulose, dibasic calcium phosphate, microcrystalline cellulose, starch and pregelatinized starch.

7. The pharmaceutical composition of any one of claims 1 to 6, wherein the other pharmaceutically acceptable excipients comprise a disintegrant selected from the group consisting of cross-linked polyvidone, croscarmellose sodium and croscarmellose sodium.

8. The pharmaceutical composition of any one of claims 1 to 7, wherein the other pharmaceutically acceptable excipients comprise a lubricant selected from the group consisting of sodium stearyl fumarate, magnesium stearate and talc.

9. The pharmaceutical composition of any one of claims 1 to 8, wherein the other pharmaceutically acceptable excipients comprise an auxiliary agent selected from the group consisting of colloidal silicon dioxide, magnesium aluminum silicate and polyethylene glycol.

10. The pharmaceutical composition of any one of claims 1 to 9, wherein the compound of formula (I) is present in an amorphous form.

11. The pharmaceutical composition of any one of claims 1 to 10, wherein the pharmaceutical composition is in a solid dosage form.

12. The pharmaceutical composition of any one of claims 1 to 11, comprising, in weight parts:

1 part of the compound shown in (I);

1 part of polyvinylpyrrolidone;

0.8 part of mannitol;

0.6 part silicified microcrystalline cellulose;

0.4 part of cross-linked polyvidone; and

0.2 part of sodium stearyl fumarate.

13.The pharmaceutical composition of any one of claims 1 to 11, comprising, in weight parts:

1 part of the compound shown in (I);

10 part of polyvinylpyrrolidone;

8 part of mannitol;


6 part silicified microcrystalline cellulose;

4 part of cross-linked polyvidone; and

2 part of sodium stearyl fumarate.

14. A method of making a pharmaceutical composition, comprising the steps of:

mixing a compound of formula (I)



(I)

with one or more solubilizing agents and/or one or more other pharmaceutically acceptable excipients to form a first mixture;

granulating the first mixture to form a granulation product; and

producing the pharmaceutical composition in a dosage form with the granulation product.

15. The method of claim 14, wherein the producing step comprises:

blending the granulation product with one or more additional pharmaceutically acceptable carrier to form a tableting mixture; and

compressing the tableting mixture into tablets.

16. The method of claim 14 or 15, wherein one or more of the compound of formula (I), the one or more solubilizing agents, and/or the one or more other pharmaceutically acceptable excipients are grinded and/or sieved before the mixing step.

17. The method of claim 16, wherein the compound of formula (I) is sieved with a 30-mesh sieve before the mixing step, and wherein the one or more solubilizing agents and/or the one or

more other pharmaceutically acceptable excipients are sieved with a 40-mesh sieve before the mixing step.

18. The method of any one of claims 14 to 17, wherein one or more of the compound of formula (I), the one or more solubilizing agents and/or the one or more other pharmaceutically acceptable excipients are grinded by mechanical grinding and/or airflow grinding.

19. A pharmaceutical composition produced by the method of any one of claims 14 to 17.

20. An effective amount of the pharmaceutical composition of any one of claims 1-13 and 19, for use as a medicament of treating nonalcoholic steatohepatitis.